Search

Your search keyword '"Hawkins, M.A."' showing total 214 results
Start Over Author "Hawkins, M.A."
214 results on '"Hawkins, M.A."'

10. Proton versus photon therapy for esophageal cancer – A trimodality strategy (PROTECT) NCT050555648

Author

Mortensen, H.R., primary, Populaire, P., additional, Hoffmann, L., additional, Moeller, D.S., additional, Appelt, A., additional, Nafteux, P., additional, Muijs, C.T., additional, Grau, C., additional, Hawkins, M.A., additional, Troost, E.G.C., additional, Defraene, G., additional, Canters, R., additional, Clarke, C.S., additional, Weber, D.C., additional, Korevaar, E.W., additional, Haustermans, K., additional, Nordsmark, M., additional, Gebski, Val, additional, Achiam, M.P., additional, Markar, Sheraz R., additional, Radhakrishna, Ganesh, additional, Berbee, Maaike, additional, Scartoni, Daniele, additional, Orlandi, Ester, additional, Doyen, Jerome, additional, Gregoire, Vincent, additional, Crehange, Gilles, additional, Langendijk, Johannes, additional, Lorgelly, Paula, additional, Blommenstein, Hedwig M., additional, Byskov, Camilla S., additional, Ehmsen, Mai L., additional, Jensen, Maria Fuglsang, additional, Freixas, Gloria Vilches, additional, and Bütoft, Rebecca, additional

Published
2024
Full Text
View/download PDF

14. A Phase 1 Trial of the Safety, Tolerability, and Biological Effects of Intravenous Enadenotucirev (EnAd), a Novel Oncolytic Virus, in Combination with Chemoradiotherapy in Locally Advanced Rectal Cancer (CEDAR)

Author

O'Cathail, S.M., primary, Qiao, M., additional, Muirhead, R., additional, Adams, R., additional, Rao, S., additional, Fisher, K., additional, Seymour, L., additional, Brown, R., additional, Lille, T., additional, Ooms, A., additional, Maughan, T.S., additional, and Hawkins, M.A., additional

Published
2023
Full Text
View/download PDF

15. Modeling Acute Chemoradiotherapy (CRT) Diarrhea Severity Using Automatically Contoured Small Bowel

Author

Shen, Z., primary, Brand, D., additional, Zhang, Y., additional, Simard, M., additional, Lopes, A., additional, Miles, E., additional, Gilbert, A., additional, West, N., additional, Blake, A., additional, Royle, G., additional, Appelt, A., additional, Maughan, T.S., additional, Sebag-Montefiore, D., additional, Collins-Fekete, C.A., additional, and Hawkins, M.A., additional

Published
2023
Full Text
View/download PDF

18. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe

Author

Kroese, T.E., Laarhoven, H.W.M. van, Schoppman, S.F., Deseyne, P., Cutsem, E. Van, Haustermans, K., Nafteux, P., Thomas, M., Obermannova, R., Mortensen, H.R., Nordsmark, M., Pfeiffer, P., Elme, A., Adenis, A., Piessen, G., Bruns, C.J., Lordick, F., Gockel, I., Moehler, M., Gani, C., Liakakos, T., Reynolds, J., Morganti, A.G., Rosati, R., Castoro, C., Cellini, F., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Henegouwen, M.I. van Berge, Hulshof, M., Dieren, J. van, Vollebergh, M., Sandick, J.W. van, Jeene, P., Muijs, C.T., Slingerland, M., Voncken, F.E.M., Hartgrink, H., Creemers, G.J., Sangen, M.J. van der, Nieuwenhuijzen, G., Berbee, M., Verheij, M., Wijnhoven, B., Beerepoot, L.V., Mohammad, N.H., Mook, S., Ruurda, J.P., Kolodziejczyk, P., Polkowski, W.P., Wyrwicz, L., Alsina, M., Pera, M., Kanonnikoff, T.F., Cervantes, A., Nilsson, M., Monig, S., Wagner, A.D., Guckenberger, M., Griffiths, E.A., Smyth, E., Hanna, G.B., Markar, S., Chaudry, M.A., Hawkins, M.A., Cheong, E., Rütten, H., Gootjes, E.C., Hillegersberg, R. van, Rossum, P.S.N. van, Kroese, T.E., Laarhoven, H.W.M. van, Schoppman, S.F., Deseyne, P., Cutsem, E. Van, Haustermans, K., Nafteux, P., Thomas, M., Obermannova, R., Mortensen, H.R., Nordsmark, M., Pfeiffer, P., Elme, A., Adenis, A., Piessen, G., Bruns, C.J., Lordick, F., Gockel, I., Moehler, M., Gani, C., Liakakos, T., Reynolds, J., Morganti, A.G., Rosati, R., Castoro, C., Cellini, F., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Henegouwen, M.I. van Berge, Hulshof, M., Dieren, J. van, Vollebergh, M., Sandick, J.W. van, Jeene, P., Muijs, C.T., Slingerland, M., Voncken, F.E.M., Hartgrink, H., Creemers, G.J., Sangen, M.J. van der, Nieuwenhuijzen, G., Berbee, M., Verheij, M., Wijnhoven, B., Beerepoot, L.V., Mohammad, N.H., Mook, S., Ruurda, J.P., Kolodziejczyk, P., Polkowski, W.P., Wyrwicz, L., Alsina, M., Pera, M., Kanonnikoff, T.F., Cervantes, A., Nilsson, M., Monig, S., Wagner, A.D., Guckenberger, M., Griffiths, E.A., Smyth, E., Hanna, G.B., Markar, S., Chaudry, M.A., Hawkins, M.A., Cheong, E., Rütten, H., Gootjes, E.C., Hillegersberg, R. van, and Rossum, P.S.N. van

Abstract

Item does not contain fulltext, BACKGROUND: Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease). However, consensus about the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer is lacking. The aim of this study was to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer. METHODS: In total, 65 specialists in the multidisciplinary treatment for oesophagogastric cancer from 49 expert centres across 16 European countries were requested to participate in this Delphi study. The consensus finding process consisted of a starting meeting, 2 online Delphi questionnaire rounds and an online consensus meeting. Input for Delphi questionnaires consisted of (1) a systematic review on definitions of oligometastatic oesophagogastric cancer and (2) a discussion of real-life clinical cases by multidisciplinary teams. Experts were asked to score each statement on a 5-point Likert scale. The agreement was scored to be either absent/poor (<50%), fair (50%-75%) or consensus (≥75%). RESULTS: A total of 48 experts participated in the starting meeting, both Delphi rounds, and the consensus meeting (overall response rate: 71%). OMD was considered in patients with metastatic oesophagogastric cancer limited to 1 organ with ≤3 metastases or 1 extra-regional lymph node station (consensus). In addition, OMD was considered in patients without progression at restaging after systemic therapy (consensus). For patients with synchronous or metachronous OMD with a disease-free interval ≤2 years, systemic therapy followed by restaging to consider local treatment was considered as treatment (consensus). For metachronous OMD with a disease-free interval >2 years, either upfront local treatment or systemic treatment followed by restaging was considered as treatment (fair agreement). CONCLUSION: The OMEC project has resul

Published
2023

25. 1251P CHARIOT: A phase I dose escalation study combining ATR inhibitor Berzosertib with chemoradiotherapy in oesophageal cancer using time to event continual reassessment (TiTE-CRM) method: Results from A1 cohort (combination with palliative RT)

Author

Mukherjee, S., primary, Lord, S., additional, Harman, R., additional, McIntosh, D., additional, Ooms, A., additional, Parkes, M., additional, Radhakrishna, G., additional, Shaw, P.H., additional, and Hawkins, M.A., additional

Published
2022
Full Text
View/download PDF

31. Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe

Author

Kroese, T.E., Hillegersberg, R. van, Schoppmann, S., Deseyne, P., Nafteux, P., Obermannova, R., Nordsmark, M., Pfeiffer, P., Hawkins, M.A., Smyth, E., Markar, S., Hanna, G.B., Cheong, E., Chaudry, A., Elme, A., Adenis, A., Piessen, G., Gani, C., Bruns, C.J., Moehler, M., Liakakos, T., Reynolds, J., Morganti, A., Rosati, R., Castoro, C., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Jeene, P., Sandick, J.W. van, Muijs, C., Slingerland, M., Nieuwenhuijzen, G., Wijnhoven, B., Beerepoot, L.V., Kolodziejczyk, P., Polkowski, W.P., Alsina, M., Pera, M., Kanonnikoff, T.F., Nilsson, M., Guckenberger, M., Monig, S., Wagner, D., Wyrwicz, L., Berbee, M., Gockel, I., Lordick, F., Griffiths, E.A., Rütten, H., Rosman, C., Verheij, M., Rossum, P.S.N. van, Laarhoven, H.W. van, Kroese, T.E., Hillegersberg, R. van, Schoppmann, S., Deseyne, P., Nafteux, P., Obermannova, R., Nordsmark, M., Pfeiffer, P., Hawkins, M.A., Smyth, E., Markar, S., Hanna, G.B., Cheong, E., Chaudry, A., Elme, A., Adenis, A., Piessen, G., Gani, C., Bruns, C.J., Moehler, M., Liakakos, T., Reynolds, J., Morganti, A., Rosati, R., Castoro, C., D'Ugo, D., Roviello, F., Bencivenga, M., Manzoni, G. de, Jeene, P., Sandick, J.W. van, Muijs, C., Slingerland, M., Nieuwenhuijzen, G., Wijnhoven, B., Beerepoot, L.V., Kolodziejczyk, P., Polkowski, W.P., Alsina, M., Pera, M., Kanonnikoff, T.F., Nilsson, M., Guckenberger, M., Monig, S., Wagner, D., Wyrwicz, L., Berbee, M., Gockel, I., Lordick, F., Griffiths, E.A., Rütten, H., Rosman, C., Verheij, M., Rossum, P.S.N. van, and Laarhoven, H.W. van

Abstract

Item does not contain fulltext, BACKGROUND: Consensus about the definition and treatment of oligometastatic oesophagogastric cancer is lacking. OBJECTIVE: To assess the definition and treatment of oligometastatic oesophagogastric cancer across multidisciplinary tumour boards (MDTs) in Europe. MATERIAL AND METHODS: European expert centers (n = 49) were requested to discuss 15 real-life cases in their MDT with at least a medical, surgical, and radiation oncologist present. The cases varied in terms of location and number of metastases, histology, timing of detection (i.e. synchronous versus metachronous), primary tumour treatment status, and response to systemic therapy. The primary outcome was the agreement in the definition of oligometastatic disease at diagnosis and after systemic therapy. The secondary outcome was the agreement in treatment strategies. Treatment strategies for oligometastatic disease were categorised into upfront local treatment (i.e. metastasectomy or stereotactic radiotherapy), systemic therapy followed by restaging to consider local treatment or systemic therapy alone. The agreement across MDTs was scored to be either absent/poor (<50%), fair (50%-75%), or consensus (≥75%). RESULTS: A total of 47 MDTs across 16 countries fully discussed the cases (96%). Oligometastatic disease was considered in patients with 1-2 metastases in either the liver, lung, retroperitoneal lymph nodes, adrenal gland, soft tissue or bone (consensus). At follow-up, oligometastatic disease was considered after a median of 18 weeks of systemic therapy when no progression or progression in size only of the oligometastatic lesion(s) was seen (consensus). If at restaging after a median of 18 weeks of systemic therapy the number of lesions progressed, this was not considered as oligometastatic disease (fair agreement). There was no consensus on treatment strategies for oligometastatic disease. CONCLUSION: A broad consensus on definitions of oligometastatic oesophagogastric cancer was found among MDTs of oeso

Published
2022

35. Use of stool collection kits delivered to patients can improve confirmation of etiology in foodborne disease outbreaks

Author

Jones, Timothy F., Bulens, S.N., Gettner, S., Garman, R.L., Vugia, D.J., Blythe, D., Hawkins, M.A., Monroe, S.S., Angulo, F.J., and Parashar, U.D.

Subjects
Communicable diseases -- Causes of, Communicable diseases -- Care and treatment, Communicable diseases -- Research, Foodborne diseases -- Causes of, Foodborne diseases -- Care and treatment, Foodborne diseases -- Research, Medical research, Medicine, Experimental, Health, Health care industry
Published
2004

39. A prospective study of diffusion-weighted magnetic resonance imaging for predicting outcome following chemoradiotherapy, in squamous cell carcinomas of the anus

Author

Muirhead, R., primary, Bulte, D., additional, Cook, R., additional, Chu, K.-Y., additional, Durrant, L., additional, Goh, V., additional, Jacobs, C., additional, Ng, S.M., additional, Strauss, V.Y., additional, Virdee, P.S., additional, Qi, C., additional, and Hawkins, M.A., additional

Published
2019
Full Text
View/download PDF

40. Pre-specified pilot analysis of a randomised pilot/phase II/III trial comparing standard dose vs dose-escalated concurrent chemoradiotherapy (CRT) in anal cancer (PLATO-ACT5)

Author

Gilbert, A., primary, McParland, L., additional, Webster, J., additional, Bell, S., additional, Copeland, J., additional, Adams, R.A., additional, Harrison, M., additional, Muirhead, R., additional, Renehan, A., additional, Sebag-Montefiore, D., additional, and Hawkins, M.A., additional

Published
2019
Full Text
View/download PDF

49. Initial results from the Royal College of Radiologists' UK national audit of anal cancer radiotherapy 2015

Author

Muirhead, R., Drinkwater, K., O'Cathail, S.M., Adams, R., Glynne-Jones, R., Harrison, M., Hawkins, M.A., Sebag-Montefiore, D., and Gilbert, D.C.

Subjects
Acute toxicity, Oncology, Radiology Nuclear Medicine and imaging, anal cancer, audit, IMRT
Abstract

Aims: UK guidance was recently developed for the treatment of anal cancer using intensity-modulated radiotherapy (IMRT). We audited the current use of radiotherapy in UK cancer centres for the treatment of anal cancer against such guidance. We describe the acute toxicity of IMRT in comparison with patient population in the audit treated with two-phase conformal radiotherapy and the previous published data from two-phase conformal radiotherapy, in the UK ACT2 trial. Materials and methods: A Royal College of Radiologists' prospective national audit of patients treated with radiotherapy in UK cancer centres was carried out over a 6 month period between February and July 2015. Results: Two hundred and forty-two cases were received from 40/56 cancer centres (71%). In total, 231 (95%) underwent full dose radiotherapy with prophylactic nodal irradiation. Of these, 180 (78%) received IMRT or equivalent, 52 (22%) two-phase conformal (ACT2) technique. The number of interruptions in radiotherapy treatment in the ACT2 trial was 15%. Interruptions were noted in 7% (95% confidence interval 0–14%) of courses receiving two-phase conformal and 4% (95% confidence interval 1–7%) of those receiving IMRT. The percentage of patients completing the planned radiotherapy dose, irrelevant of gaps, was 90% (95% confidence interval 82–98%) and 96% (95% confidence interval 93–99%), in two-phase conformal and IMRT respectively. The toxicity reported in the ACT2 trial, in patients receiving two-phase conformal in the audit and in patients receiving IMRT in the audit was: any toxic effect 71%, 54%, 48%, non-haematological 62%, 49%, 40% and haematological 26%, 13%, 18%, respectively. Conclusions: IMRT implementation for anal cancer is well underway in the UK with most patients receiving IMRT delivery, although its usage is not yet universal. This audit confirms that IMRT results in reduced acute toxicity and minimised treatment interruptions in comparison with previous two-phase conformal techniques.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results